Analysis of time to 5% decline of baseline FEV1 % predicted
| Unadjusted HR | Adjusted HR* | |
| <1 exacerbation/year | 1.29 | 1.33 |
| versus | 95% CI 0.95 to 1.77 | 95% CI 0.96 to 1.84 |
| 1–2 exacerbations/year | p=0.11 | p=0.08 |
| <1 exacerbation/year | 1.47 | 1.55 |
| versus | 95% CI 1.07 to 2.01 | 95% CI 1.10 to 2.18 |
| >2 exacerbations/year | p=0.02 | p=0.01 |
↵* Adjusted for age, sex, body mass index, infection with Burkholderia cepacia, transmissible Pseudomonas aeruginosa, baseline forced expiratory volume in 1 s (FEV1), cystic fibrosis co-morbidities and maintenance therapies.